Leukemia, B-Cell, Chronic
Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AdvanCellAcadesine
SanofiAlemtuzumab
Clinical Trials (2)
Total enrollment: 300 patients across 2 trials
Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients
Start: Dec 2007Est. completion: Dec 2010
Phase 1/2Completed
Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)
Start: Jan 2004Est. completion: Nov 2006300 patients
N/ACompleted
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
2m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
2m ago
Office Administrator
SystImmune
2m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
13m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
16m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
16m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (100% of programs)
2 companies competing in this space